123 related articles for article (PubMed ID: 38291863)
21. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
[TBL] [Abstract][Full Text] [Related]
22. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
[TBL] [Abstract][Full Text] [Related]
23. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
[TBL] [Abstract][Full Text] [Related]
24. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Mohamed YI; Duda DG; Awiwi MO; Lee SS; Altameemi L; Xiao L; Morris JS; Wolff RA; Elsayes KM; Hatia RI; Qayyum A; Chamseddine SM; Rashid A; Yao JC; Mahvash A; Hassan MM; Amin HM; Kaseb AO
Oncotarget; 2022 Dec; 13():1314-1321. PubMed ID: 36473155
[TBL] [Abstract][Full Text] [Related]
25. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
[TBL] [Abstract][Full Text] [Related]
26. Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab.
Ledenko M; Mercado L; Patel T
Am J Clin Oncol; 2024 Mar; 47(3):105-109. PubMed ID: 38047447
[TBL] [Abstract][Full Text] [Related]
27. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
[TBL] [Abstract][Full Text] [Related]
28. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Toshida K; Itoh S; Yoshiya S; Nagao Y; Tomino T; Izumi T; Iseda N; Toshima T; Ninomiya M; Yoshizumi T
J Gastroenterol Hepatol; 2024 Mar; 39(3):576-586. PubMed ID: 38084637
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
[TBL] [Abstract][Full Text] [Related]
31. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
[TBL] [Abstract][Full Text] [Related]
32. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
[TBL] [Abstract][Full Text] [Related]
33. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yamauchi Y; Saeki I; Yamasaki T; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Nishimura T; Tanabe N; Oono T; Matsumoto T; Ishikawa T; Marumoto Y; Matsukuma S; Shindo Y; Tokumitsu Y; Yoshimine S; Murakami J; Tanaka T; Kimura S; Hoshii Y; Hamano K; Nagano H; Takami T
Hepatol Res; 2023 Jul; 53(7):681-686. PubMed ID: 36826420
[TBL] [Abstract][Full Text] [Related]
34. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
Kaneko Y; Kaneshiro M; Watanabe H
Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
[TBL] [Abstract][Full Text] [Related]
36. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
Gao X; Zhao R; Ma H; Zuo S
BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
[TBL] [Abstract][Full Text] [Related]
38. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
39. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
40. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Kosaka Y; Kawaoka T; Kosaka M; Shirane Y; Miura R; Murakami S; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Aikata H
Intern Med; 2023 Jun; 62(12):1771-1774. PubMed ID: 36328580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
